Currently out of the existing stock ratings of Bill Maughan, 10 are a BUY (62.5%), 6 are a HOLD (37.5%).

Bill Maughan

Work Performance Price Targets & Ratings Chart

Analyst Bill Maughan, currently employed at CANACCORD, carries an average stock price target met ratio of 27.78% that have a potential upside of 2.79% achieved within 29 days.

Bill Maughan’s has documented 31 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FATE, Fate Therapeutics at 10-May-2024.

Wall Street Analyst Bill Maughan

Analyst best performing recommendations are on IMCR (IMMUNOCORE HOLDINGS LTD).
The best stock recommendation documented was for IMCR (IMMUNOCORE HOLDINGS LTD) at 2/29/2024. The price target of $63 was fulfilled within 8 days with a profit of $4.22 (6.28%) receiving and performance score of 7.85.

Average potential price target upside

DCTH Delcath Systems FATE Fate Therapeutics IPSC Century Therapeutics NKTX Nkarta  IMCR Immunocore Holdings Ltd MRNA Moderna

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$22

$13.32 (153.46%)

$22

1 months 29 days ago

0/8 (0%)

$14.05 (176.73%)

Buy

$21

$12.32 (141.94%)

$18

1 years 28 days ago

0/5 (0%)

$16.4 (356.52%)

Buy

$13

$4.32 (49.77%)

$25

1 years 1 months 19 days ago

1/4 (25%)

$7.59 (140.30%)

245

Buy

$20

$11.32 (130.41%)

1 years 1 months 19 days ago

1/2 (50%)

$14.59 (269.69%)

36

Buy

$14

$5.32 (61.29%)

$17

1 years 10 months 14 days ago

0/2 (0%)

$11.06 (376.19%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Bill Maughan is most bullish on?

Potential upside of $45.8 has been obtained for MRNA (MODERNA)

Which stock is Bill Maughan is most reserved on?

Potential downside of $5.78 has been obtained for FATE (FATE THERAPEUTICS)

What Year was the first public recommendation made by Bill Maughan?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?